Abstract

As the largest super-family of membrane bound receptor proteins, G Protein-Coupled Receptors (GPCRs) play crucial roles not only in everyday physiology, but many pathologies. Although over a third of FDA approved pharmaceuticals target GPC Rs, many prospective drug candidates fail due to on-target but undesirable effects. Such adverse effects are likely due to the pleiotropic nature of GPCR signalling pathways. Here, the development of a novel biosensor platform for investigating this pleiotropy is outlined and the first iteration presented. The Multi-Response Element GPCR Sensor (MREGS) allows for the simultaneous investigation of five signalling events downstream of GPCR activation using a multiplexed based assay system (Sarrion-Perdigones et al., 2019). This system can now be applied to search for more pathway specific pharmaceuticals with fewer side effects.